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Abstract
Recent findings suggest that rare variants play an important role in both monogenic and common diseases. Due to their
rarity, however, it remains unclear how to appropriately analyze the association between such variants and disease. A
common approach entails combining rare variants together based on a priori information and analyzing them as a single
group. Here one must make some assumptions about what to aggregate. Instead, we propose two approaches to
empirically determine the most efficient grouping of rare variants. The first considers multiple possible groupings using
existing information. The second is an agnostic ‘‘step-up’’ approach that determines an optimal grouping of rare variants
analytically and does not rely on prior information. To evaluate these approaches, we undertook a simulation study using
sequence data from genes in the one-carbon folate metabolic pathway. Our results show that using prior information to
group rare variants is advantageous only when information is quite accurate, but the step-up approach works well across a
broad range of plausible scenarios. This agnostic approach allows one to efficiently analyze the association between rare
variants and disease while avoiding assumptions required by other approaches for grouping such variants.
Citation: Hoffmann TJ, Marini NJ, Witte JS (2010) Comprehensive Approach to Analyzing Rare Genetic Variants. PLoS ONE 5(11): e13584. doi:10.1371/
journal.pone.0013584
Editor: Alfred Lewin, University of Florida, United States of America
Received June 3, 2010; Accepted September 20, 2010; Published November 3, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: TJH was supported by National Institutes of Health (NIH) R25CA112355 training grant. NJM was supported by NIH grant R01GM072859 (NIGMS). JSW
was supported by NIH grants R01CA88164 and U01CA127298. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: WitteJ@humgen.ucsf.edu
Introduction
There is increasing evidence supporting the role of rare variants
in both monogenic and complex diseases [1–6]. In parallel with
this new sequencing technologies are providing an avenue for
effective detection of rare variants in the human genome [7]. Such
technologies are helping the 1000 Genomes Project catalogue less
common variants (http://www.1000genomes.org). These advanc-
es in our ability to study rare variants should substantially improve
our insight into the genetic basis of health and disease.
Evaluating the potential impact of rare variants on disease is
complicated, however, by their uncommon nature. Several
approaches have been proposed for the analysis of rare variants.
On the one extreme is collecting such an enormous study sample
that rare variants are detected sufficiently often to allow for testing
eachvariantindividually;forexample,Nejentsevetal.[8]discovered
a rare variant with minor allele frequency (MAF) 0.46% in Type I
Diabetes cases and 0.67% in controls, using 17,730 individuals.
Evaluating each individual rare variant will generally not be effective
for smaller sample sizes or for variants that have even lower MAFs
than that of Nejentsev et al. [8] due to data sparsity. In particular,
conventional analyses may produce extremely unstable estimates of
rare variant effects on disease and be essentially uninformative.
An alternative is to combine rare variants together into groups
in a reasonable manner so they can be efficiently analyzed. Note
that when we use ‘‘efficient’’ in this manuscript, we will always be
referring to statistical power; computational time will be referred
to as runtime. One might simply tabulate in cases and controls the
number of individuals that have any rare variants (e.g., within a
given locus), and contrast these counts. Morgenthaler et al. [9]
have termed this the Cohort Allelic Sums Test (CAST). This
approach essentially assumes that the rare variants have similar
effects on disease. In other words, CAST gives equal weights to all
rare variants combined together. It also treats individuals who are
heterozygous and homozygous in an identical manner, although
there will be few of the latter when studying rare variants.
Another option is to somehow weight each rare variant and
then combine them. The optimal approach will upweight the
variants most likely to cause disease and downweight variants that
have no effect on disease. The weights could be calculated in a
number of different ways. Madsen and Browning [10] propose
weighting each allele by the inverse of the estimated standard
deviation of the total number of mutations in the controls. Rare
variants can also be simultaneously analyzed with common
variants in a multivariate test, as in the Combined Multivariate
and Collapsing (CMC) method [11]. Here, a multivariate test is
constructed using a term for collapsed rare variants plus terms for
each of the common alleles. This allows for collapsing variants
only when needed due to their rarity, and analyzing more
common variants on an individual basis.
The decision to aggregate rare variants – with or without
explicit weighting – requires a number of strong assumptions
about the similarity of their effects on disease. This raises a critical
unanswered question: how to best combine rare variants for
analysis? For instance, one might choose a minor allele frequency
threshold to define what is ‘‘rare,’’ or choose a weighting scheme
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decide to only aggregate nonsynonymous variants in the coding
regions [9] as these might be the most likely to cause disease [12].
Such a grouping could be further refined to only nonsynonymous
variants that lead to putatively deleterious mutations that impair
the function of the protein (e.g., using predictive algorithms such as
SIFT [13], PMUT [14], or PolyPhen [15]). However, such
algorithms vary in the information used, and can give different
results, which would lead to different groupings of rare variants.
For example, we found that the agreement among SIFT, PMUT,
and PolyPhen in predicting the impact of mutations was only 52%
in the data we used for our simulation study (discussed below).
Clearly it is very difficult to define a priori what rare variants should
be aggregated into a single group for analysis.
Two methods have recently been proposed to collapse rare
variants in a data-driven manner. Price et al. [16] extend the
CAST [9] and the weighted approach [10] by testing multiple
allele frequency thresholds, rather than choosing one fixed
threshold, and also extend the test to quantitative traits. However,
they assume that all rare variants are deleterious; while this may be
a reasonable assumption for many diseases [2], there is also the
possibility that some rare variants are protective. Han and Pan
[17] allow for both deleterious and protective variants by letting
the data determine whether an allele should be protective or
harmful when collapsing, and also suggests collapsing common
variants into the test. We combine and further extend these
approaches in a more flexible data-driven model to decide how
best to group rare variants for association analysis.
Our approach considers multiple possible groupings, choosing
the ‘‘best’’ set based on statistical criteria, and correcting by
permutation. One can use prior information from several sources
to define these groupings; e.g., different protein coding function
algorithms. Alternatively, or in addition, one can use data-driven
methods to define these groupings based only on statistical
criterion; e.g., all possible allele frequencies, all possible subsets
of rare variants, or a ‘‘step-up’’ approach we propose here. That is,
we use the data to decide whether a variant should be deleterious
or protective, or whether the variant should even be in the model
at all. We use a simulation study to evaluate these approaches. The
simulations are based on data from deeply sequenced candidate
genes in the one-carbon folate metabolic pathway [18].
Methods
General framework
Assume that we have undertaken a study of the relationship
between K genetic variants and a phenotype Y among I
individuals. Let Xik be the additive coding for a marker (i.e., the
number of minor alleles individual i has at variant k); others can
be considered, but a dominant coding will be almost identical to
an additive coding for a rare variant. Then a flexible disease model
for the relationship can be given by
g(Yi)~a0z
X
k
bkXik, ð1Þ
where Yi is an individuals phenotype (dichotomous or continuous)
and g is a link function (e.g., logit for logistic regression or the
identity for linear regression). With rare variants, however, the
data is too sparse to estimate each individual’s bk. For example,
suppose we try to fit a logistic regression to test for the genetic
association of a rare variant with disease. Without an enormous
sample size, the estimate of a single rare variant’s effect on Y (^ b bk)
may be extremely unstable and essentially uninformative.
An alternative is to somehow aggregate multiple rare variants,
and leverage their combined strength to improve estimation. This
can be formalized with a second-stage model for the parameters of
interest, a vector of coefficients bk
b~ªWzd, ð2Þ
where ª is a vector of combined genetic effects (e.g., a single
collapsed effect, or two terms for a protective and deleterious effect)
that we want to evaluate; W is a second-stage design matrix that
incorporates information on factors about the genetic variants; and
d is a random effect. Equation 2 is essentially a prior model that
distinguishes how one can ‘‘borrow information’’ across rare
variants. Together equations 1 and 2 define a hierarchical model
that can be used to incorporate complex interrelationships among
the variants and their putative effects on disease.
However, most of the existing rare variant approaches
essentially model a single combined genetic effect c, aggregating
all of the data features into a single wk for each SNP, and assume
d~0. We build on these approaches, and for focus and tractability
do not explore a fully parametrized hierarchical model; further
details on the potential value of this approach are given in the
discussion. Now combining Equations 1 and 2 gives the model
g(Yi)~a0zc
X
k
wkXik
"#
: ð3Þ
That is, one is essentially modeling and estimating the effect of a
weighted combination of variants
P
k wkXik
  
.
We will explore different ways to model wk in this paper, from
data-driven methods to those based completely on prior
information. There have been several approaches proposed to
modeling wk in the literature. The simplest is to set wk~1 and
sum them together. This is similar to the CAST approach [9],
which uses an indicator variable for the presence of any rare
variant. Here we use a multiplicative model wk~akskvk, where ak
is a continuous weight (e.g., to incorporate allele frequencies), sk
determines the direction of the variant effect (deleterious or
protective), and vk is an indicator variable determining whether
the allele belongs in the model for variable selection. Note that in
our description of these parameters below, we will be using the
data to estimate them; we will correct for this by permutation at
the end of the procedure.
For the continuous weight ak, one can incorporate allele
frequency information (or set this to 1). For example, Madsen and
Browning [10] consider all alleles to be deleterious, and set ak for
dichotomous traits to the inverse square root of the expected
variance based on allele frequencies p?
k in the controls,
1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p?
k(1{p?
k)
p
, with pseudocounts (i.e., adding 1 to the numerator
and denomerator when estimating p?
k to prevent any zero weights).
Price et al. [16] extend this to continuous traits by estimating the
allele frequency pk including all samples.
If we believe all variants have a deleterious effect, we can set sk
to be 1, and ignore this parameter. Otherwise, we can let the data
decide how to specify sk. Han and Pan [17] addressed this first
fitting a marginal regression model for the association between the
variant and disease, and then flipping the coding of the genotype
when the estimated coefficient is negative and reaches a certain
significance threshold. We use a slightly different method for rare
variants. For dichotomous traits, if an allele is more prevalent in
controls than cases, we set sk~{1 to indicate it is likely
deleterious, and if it is more prevalent in cases than in controls,
we set sk~1 to indicate it is protective. For continuous traits we
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marker; this is equivalent to the sign of the regression coefficient,
just slightly faster to calculate.
Lastly, we have vk, which determines whether a variable enters
into the model. One example would be to set this by a hard minor
allele frequency threshold (e.g., as in CAST [9]). However, we
may also wish to try the approach at several allele frequency
thresholds, or even all possible allele frequency thresholds [16]. In
this case, we change our notation so that we are considering a set
W of models with elements indexed by a vector l~(la,ls,lv) as
wl
k~w
la,ls,lv
k ~a
la
ks
ls
kv
lv
k. Testing all allele frequencies would be
equivalent to running the test for each v
lv
k~I pkvulv fg , where u is
the set of unique allele frequencies.
Another example ofhow to chose vk is as an indicatorfor variants
in coding regions, since they may be more likely causal than those
elsewhere [12]. We may wish to consider only those mutations that
are nonsynonymous, and in particular those that are highly
deleterious. Several algorithms exist for estimating the magnitude
of the deleterious effect of mutations on protein function, but they
do not always agree. Again, we might even also consider using
several algorithms to define different groups to test. One may wish
to use a consensus of all of these functional designations to group
rare variants, or even use continuous information from the protein
coding function algorithms. We can combine this with our ideas for
testing multiple allele frequency thresholds.
There is one other model we will introduce for vk, but it will be
clearer after we describe the test statistic and understand its
computational runtime. To speed up the approach one could use
linear regression for all phenotypes, instead of logistic regression
[16,17]. We instead take the mean centered score of c from
Equation 3 divided by the empirical variance: xl~
P
i,k Ul
ik
   2
=
P
i
P
k Ul
ik
   2, where U
la,ls,lv
ik ~a
la
ks
ls
kv
lv
k Xik{X:k
  
Yi{Y
  
,
Y~
P
i Yi=I, and X:k~
P
i Xik=I. Then xl follows a chi-
squared distribution with one degree of freedom. When we are
considering a set of models W for wk, then the final test statistic of
the procedure is given by xmax~maxl xl. Then to compute the p-
value of the test, we permute the phenotypes of the individuals,
and recompute x(p)
max for permutation p, following the entire
procedure as before. Then the p-value for P permutations is given
by
P
p I(x(p)
max§xmax)=P.
With the computational complexity of testing multiple weights
in mind, we also consider a data-driven method for specifying vk.
The approach we described above for testing all allele frequencies
is computationally of order linear time in the number of variants.
In contrast, having lv index all possible subsets of variants is on the
order of factorial time in the number of variants, and is too
computationally intensive for all but the smallest genes. Instead,
we propose a ‘‘step-up’’ approach that has a computational
runtime inbetween these two methods. This is similar to stepwise
regression, but instead of selecting additional independent
predictors, the step-up approach chooses the best combination
of rare variants into a single aggregated group. With this approach
we first compute the univariate test statistic xk1 for each variant k1.
We then determine the ‘‘best’’ (i.e., maxk1 xk1) of these models;
denote this model k?
1, with test statistic mk?
1. We then build on the
model with variant k?
1 by computing the test statistic mk?
1,k2 for
each marker k2 and the best marker k?
1 from the first approach.
Denote the best added variant of this second step as k?
2.I f
mk?
1§mk?
1,k?
2, then the algorithm terminates. Otherwise, the
algorithm continues until mk?
1,...,k?
t{1§mk?
1...k?
t . Again the p-value
is obtained by permutation, repeating the entire procedure for
each phenotype permutation. This algorithm’s speed is of at worst
a squared number of time in the number of variants.
We can further extend this to allow the set of all models
considered to include any combination of the approaches from
above, restricted to being computationally feasible. That is, l could
index across all of the steps in the step-up model based on SIFT
functional markers, and all of the steps in the step up model based
on PMUT functional markers. This effectively uses the ‘‘best’’ of
these two procedures. However, the more rare variant groupings
and tests considered, the less efficient and more computationally
intensive the approach will be compared to that which most
accurately tests the true underlying model. When the disease
model is not well understood, as is probably the case for many rare
variants, it is advantageous to consider several different groupings
and/or tests. In our simulations, we explore this trade-off between
considering many possibilities and making strong assumptions.
Models for variant weights
In the previous section we described a general framework and
strategies for constructing a model for the variant weights wk and
evaluating an aggregated genetic effect on disease c.H e r ew e
enumerate the models that we will compare in our subsequent
simulations (distinct from the models we will use to generate our
data). We first investigated the following models with sk~1 (i.e., all
variants aredeleterious) andak~1 (i.e.,they areequallydeleterious):
1. MAFƒ0:01: vk~Ifpkv0:01gfk, where fk is defined:
(a) SIFT: fk~Ifk[SIFTg (this will be the true generating model, so
as if we knew the true underlying model);
(b) Nonsynonymous: fk~Ifk[Nonsynonymousg (modeling all mutations
that alter protein coding function).
1. This is similar to CAST, but summing
P
k Xik rather than an
indicator variable of any mutation.
2. MAFƒ0:05: Same as (1), but vk~Ifpkv0:05g.
3. All MAF: v
lv
k~Ifpkvulvgfk, where fk is (i.e., all allele frequencies
as described above)
(a) Nonsynonymous: fk~Ifk[Nonsynonymousg;
(b) All protein coding: f 1
k ~Ifk[SIFTg, f 2
k ~Ifk[PMUTg, f 3
k ~
Ifk[Polypheng (i.e., try several protein coding functions since
we will see they often differ);
(c) Non-generating protein coding: f 1
k ~Ifk[PMUTg, f 2
k ~Ifk[Polypheng
(i.e., exclude the protein coding function grouping informa-
tion actually used to generate the data, and see if the other
grouping methods, PMUT or polyphen, can still detect an
association).
4. Step: v
lv
k based on the ‘‘step-up’’ approach described above.
In addition to these, we then fit models 1?{4?, the same as
1{4 but with ak set to the inverse variance of variant k using
controls for dichotomous traits, and all subjects for continuous
traits. Next we refit both models in 3 and 3?, and choosing the
‘‘best’’. Finally, we tested 1{4 with sk~+1 (i.e., signed, as
described previously). Note that in these scenarios the weights
presented here do not make as much sense for protective variants
(i.e., especially weighting based on allele frequency in controls).
Simulation design
We investigated several different rare variant disease models.
Dichotomous traits were simulated using the disease model given
in equation 1 under a logit link, and continuous traits with the
identity link. We simulated a range of odds ratios (2 to 5) for
Analyzing Rare Variants
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0.6) for continuous traits; a wide range of values are used here
because rare variants are expected to have moderate to high
penetrances [19,20]. We also undertook simulations for an odds
ratio of 1 or mean difference 0 to make sure the tests maintain the
proper type I error. For dichotomous traits, a0 was chosen to keep
the population prevalence fixed at 0.01. Other values for the
population prevalence were considered, but did not materially
affect the results. For continuous traits, a0 is irrelevant.
The variant data was generated using the haplotype frequencies
across genes from an existing sequence-level dataset. One thousand
cases weredrawn according to the joint distribution of Y~1 and X,
and 1000 controls from the joint distribution of Y~0 and X,o r
2000 individuals with a quantitative trait. A vector of genetic
variants X was drawn from haplotype frequencies of 480 individuals
in which the coding regions of 16 genes in the folate metabolic
pathway[18] weresequenced,inthe California NewbornScreening
Program; more results are given in the results section.
We ran 500 simulations per gene, and averaged the empirical
power over all of the genes according to a type I error rate of 0.05
(i.e., average power for gene-specific detection, not pathway). We
ran 500 permutations for each test (except CMC, for which an
asymptotic test is available [11]). In practice one might wish to run a
larger number of permutations for regions suggestive of association.
500 permutations were run here for simulation speed, as many tests
were considered, and should be accurate for the simulations. Unless
otherwise stated, we used the SIFT algorithm to determine if alleles
were considered intolerant (including those with low confidence)
and thus associated with disease, or tolerated and not associated
with disease [13]. The power plots we present are the average over
these genes. In each gene, we tried to construct and normalize our
coefficients in such a way that the maximum contribution of any
allele was less than or equal to the odds ratio.
We ran several simulations for dichotomous traits with the
following values of bk (Equation 1):
1. Constant effect for all variants: Let y be the odds ratio, and 0:01 be
the cutoff for whether an allele is rare and deleterious. Define
bk~log(y)Ifk[SIFTgIfpkv0:01g.
2. Varying the causal frequency: Since we do not actually know the
true allele frequency, we undertook several other simulations
varying the ‘‘causal’’ rare allele frequency. That is, we allowed
the cutoff Ps to follow a discrete uniform distribution according
to the allele frequencies in each gene that were less than 0.05,
varying this for each simulation. We define bk~log(y)
Ifk[SIFTgIfpkvPsg.
3. Continuous penetrance of disease: Here, let fk be the continuous
coding of SIFT [13] for variant j, which ranges from 0 to 1,
with 0 being predicted as more deleterious. We define
bk~log 1z(y{1)
1{fk
max(1{f)
  
. Variants that have a higher
probability of deleteriousness as per the SIFT algorithm are
simulated to increase the odds of disease proportionately
higher.
4. Incorporating rare and common variants: We control how much more
deleterious a rare variant isthan more commonvariants with the
parameter F and define bk~log 1z(y{1)
min(p)
pk
   1=F "#
Ifk[PMUTg. When F~1, rarer variants have a very strong effect,
and common variants have almost no effect. For larger values of
F, common variants have an increasing effect on disease. Note
that here we use PMUT to increase the number of genes with
deleterious common variants (four rather than one with SIFT).
5. Incorporating protective and deleterious alleles: We randomly parti-
tioned each gene such that approximately 50% of the total
allele frequency of rare functional variants were deleterious,
and the rest protective. We define bk~log(y)skIfk[SIFTg
Ifpkv0:01g, where sk was {1 for deleterious alleles and 1 for
protective alleles. We then repeated this with approximately
75% of the total allele frequency as deleterious.
We also reran simulations 1 and 5 for continuous traits. Here we
replace the odds ratio log(y) with the mean difference for each
additional dosage of a variant allele, and sampling the trait
according to a N(
P
k bkXik,1) distribution.
Results
Dataset description
The deep sequenced dataset on which our simulations were
based was rich with rare variants; out of 764 putative SNPs, 653
had allele frequencies less than 5%, and 583 had an an allele
frequency less than 1%. In the nonsynonymous regions of these
genes we compared the SIFT [13], PMUT [14], and PolyPhen
[15] methods of predicting whether the variants were deleterious
protein coding mutations. Figure 1 shows the number of rare
variants as characterized by these algorithms, for varying allele
frequencies. We found that there was limited concordance among
these methods (at best 52%, Table 1). This is similar to Chun et al.
[21]. Nevertheless, the low concordance among these three
algorithms is actually beneficial for our simulations because it
adds variability reflecting reality. When we use SIFT to generate
the disease model, it is interesting to assess how well the other
approaches work. Data from 13 of the 16 genes were included in
the analysis because each of the 13 had at least one intolerant
nonsynonymous mutation as predicted by the SIFT algorithm (full
details of this and other methods are in Table 1), whereas the
remaining 3 had no predicted deleterious changes.
Simulation results
Each simulation enumerated above is highlighted in Figures 2
and 3. In these figures, the different scenarios are distinguished by
the three indices separated by commas along the X-axes. The first
label indicates which of the four tests was used (i.e., the model for
ak): constant (C), weighted (W), or both constant and weighted (B).
The second label is for the parameter sk and indicates whether the
sign was set to a constant 1 (z), or allowed to vary as described
above (z={). The third label is for the model parameter vk, and
indicates whether the test was done restricting to a particular
algorithm’s deleterious call (e.g., SIFT) or all nonsynonymous
changes (NS), and what range of alleles or groupings that test was
applied to. The latter corresponds to: the exact generating alleles
(Perf for ‘‘perfect’’, i.e., testing only the alleles contributing to
disease), all allele frequencies (MAF), all functional groupings (F),
all functional groupings except that used to generate the data
(*F), a hard allele frequency threshold (e.g., ‘‘v0:05’’), the CMC
method with a hard threshold (only run for common variants,
simulation 4), or the step-up algorithm described in the methods
section (step). Unless otherwise stated, the order of the tests in the
plots are by the most overall powerful (averaged over the 4 ORs or
mean differences).
Figure 2A shows the results from simulation 1, the fixed MAF
threshold of 0.01. The weighted method generally performs better
than constant weights (even when we are testing the exact markers
we use to generate, Perf) and appreciably better than applying
constant weights to all minor allele frequencies as does using a
fixed threshold (e.g., v0:01 or v0:05). We also note that the step-
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the variants does not make the power much worse even though all
SIFT variants are assumed deleterious. Figure 2B shows the results
from simulation 2, under the more realistic scenario with different
allele frequencies generating each simulation. Here the step-up
method performs the best, aside from the unrealistic Perf test. In
comparison with simulation 1, we see a more dramatic power
reduction for the unweighted (C) tests that allow for multiple
MAFs. Figure 2C shows the results from simulation 3, with a
continuously generated deleteriousness of alleles. Surprisingly, the
weighted method with a MAFv0:05 for aggregating variants has
the most power in this figure. However, the step-up is nearly
identical (C or W). As above, the weighting by minor allele
frequencies in controls (W) generally worked better than not
weighting (C). In these tests a similar step-down approach was
tried, but it did not work well (results not shown).
We then looked at the effect of common variation according to
the PMUT algorithm in simulation 4 (4 genes had common
variants, Figure 1) [14]. In Figure 2D we vary the parameter F for
each situation, and fix the odds ratio at 2. Here the order of the
tests is not as informative as it was for the other plots; it is best to
separately consider the different approaches’ power for each value
of F in Figure 2D. To emphasize this, Figure 2D is ordered by the
power at F~5. For F~1 and F~2, the rare variant methods
perform the best. Step-up performs well, but we see a small power
loss for the z={ approach, unlike before. However, if common
variants have any appreciable effect on disease (F§3), then the
CMC approach works best. This is likely because it is more flexible
and does not assume that the more common variants have the
same effect at the expense of a few degrees of freedom. As
expected, we also saw that requiring a hard cutoff of MAFv0:01
or v0:05 performed poorly (Figure 2D).
In the top panels of Figure 3 we can see the effect of protective
and deleterious mutations (simulation 5). Figure 3A shows a
50%=50% split, while 3B shows a 75%=25% split of deleterious vs.
protective variants. It is not surprising that the methods which sign
variants based on case-control differences generally performed the
best here, especially for the 50%=50% split. What is slightly
surprising is that the unsigned step-up routine performs nearly as
well as the signed step-up routine that does not. Even the constant
threshold performs well, if it is signed. The unsigned methods look
slightly better in the 50%=50% split than they do in the 75%=25%
split, although the signed methods are preferred.
When considering continuous traits our simulations gave
generally similar results as seen for dichotomous traits. Figure 3C
shows results for simulation 1? - data generated from SIFT
prediction where all variants with MAFv0:01 are causal. Results
are similar to simulation 1 with the weighted and step-up
Figure 1. Deleteriousness of variants detected by sequencing one-carbon folate metabolic pathway candidate genes. For each gene,
the number of variants from sequencing that are nonsynonymous, and then deemed deleterious by three different methods (SIFT [13], PMUT [14], or
PolyPhen [15]) plotted by ranges of the variant’s minor allele frequency. The SIFT designations are generally used here for our simulation studies
(except those with common variants, where we used PMUT designations to have more genes with deleterious mutations for simulation purposes).
doi:10.1371/journal.pone.0013584.g001
Analyzing Rare Variants
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13584approaches performing best, and allowing for any MAF doing
worse. Figure 3D presents results for simulation 5? for the
50%=50% split. For continuous data, the signed tests show even
more benefit than for dichotomous traits. In fact, assuming that all
variants are deleterious works quite poorly, except for the step-up
approach, which still did reasonably well.
Discussion
We have compared several different approaches to rare variant
analysis that incorporate varying amounts of prior information in
deciding how to aggregate such variants. When one does not know
how rare variants affect disease, and is hesitant to make the strong
assumptions required to collapse them together, the completely
agnostic step-up approach presented here may be the most
appropriate. It performed either the best, or close to the best
(excluding the ‘‘perfect’’ but unrealistic tests) in the various
situations considered.
When it is possible that both protective and deleterious variants
are present, we found it useful to sign variants (although little
difference between stepwise and signed stepwise). Signing variants
greatly improved the efficiency when both protective and
deleterious variants are present, although some efficiency was lost
when only deleterious alleles were present. The weighting schemes
we considered based on allele frequency (models for ak) generally
did not work well when both protective and deleterious variants
were present. However, these weights were designed for the
situation when all alleles are deleterious, and do improve the
efficiency in those situations (with the exception of step-up, where
there is little difference). Using a hard cutoff performed relatively
poorly unless it accurately reflected the underlying disease model;
aside from that, a slightly higher allele frequency threshold
generally worked better. When using a slightly softer assumption of
testing all MAF thresholds, we found that incorporating functional
information from protein coding function algorithms generally
improved the efficiency of the test, and added only a minor extra
computational burden. Note, however, that we used the SIFT
algorithm to generate this data in our simulations, so it is biased
towards using that information. Yet even the other protein coding
function algorithms (e.g., PMUT, PolyPhen) did well with all MAF
when this information was not available. The more flexible step-up
approach does not need to rely on having such information.
Our simulations focused on combining rare variants within
particular genes. One can extend this approach to pathways,
exomes, or entire genomes, although the latter may be computa-
tionally challenging. Some computational time may be saved by
using an adaptive permutation that stops earlier for genes or
regions that appear to have no impact. For exomes, one could also
further collapse entire pathways instead of genes. A fast analysis of
different pathways could be done by testing each gene individually,
and combining the resulting p-values with the Fisher product test
statistic [10], or applying another step-up approach to further
combine the aggregated scores from each gene. Testing all MAF
instead of the step-up approach is also an alternative if
computational time is an issue [16].
Many complex diseases are likely due to a combination of rare
and common variants. One can jointly analyze rare and common
variants as in the CMC approach [11], but the rare variants must
have a large enough effect size to contribute much to the efficiency
of the test. Note that we did not consider various groupings for the
CMC test because multivariate logistic regression was prohibi-
tively slow for us to run many permutation tests in the simulations.
An alternative may be using linear regression. In practice a
combination of some of rare variant aggregation methods with the
CMC method might be the most appropriate for many risk loci.
Another promising approach for rare variant analysis is
hierarchical modeling [22–25]. We presented a general model in
equations 1 and 2 that is essentially hierarchical, and even made
some explicit prior assumptions about the variant effects
distribution (e.g., a point mass with no variability). Further
extending these models with other hyperparameters offers an
opportunity to potentially improve upon existing rare variant
techniques and is an important area of future research.
As with any genetic analysis, one may need to adjust for
potential confounding (e.g., due to population stratification).
Dichotomous covariates, or covariates with only a few levels,
can be included easily in these rare variant approaches by
stratifying on them. Otherwise the residuals of a logistic/linear
repression of the trait on the covariates of interest can be fit with
the continuous version of the test. One could also just use the
model in Equation 1 adjusting for covariates; here, one might
always use linear regression as it will be faster. The score test from
linear regression is nearly the same as the score test from logistic
regression, with the modification that the information contribu-
tions of each subject is weighted by pi(1{pi), where
pi~Pr(Yi~1Dcovariates), rather than an assumed constant
residual variance as in ordinary linear regression.
In summary our simulations suggest that the step-up approach
works quite well without requiring a priori information about how
to aggregate rare variants for analysis. This agnostic approach was
generally one of the best under a broad range of scenarios, and
should perform well under disease models different than those
Table 1. Protein Function by Gene.
SIFT PMUT PolyPhen Count
I Path Prob 8
I-LC Path Prob 2
I Neut Prob 9
I-LC Neut Prob 1
tolerated Neut Prob 1
I Path Poss 3
tolerated Path Poss 1
I Neut Poss 6
I-LC Neut Poss 2
tolerated Neut Poss 6
I Path Ben 2
I-LC Path Ben 4
tolerated Path Ben 24
I Neut Ben 13
I-LC Neut Ben 1
tolerated Neut Ben 43
Overlap of SIFT [13], T - Tolerated, I - Intolerant (tolerance index score ƒ0:05,a s
suggested by the software documentation), I-LC - Intolerant with Low
Confidence (tolerance index score ƒ0:05, but median sequence conservation
score §3:35); PMUT [14], Neut - Neutral, Path - Pathological; and PolyPhen [15],
Ben - Benign, Poss=Possibly Damaging, Prob=Probably Damaging. Bolded
counts indicate where one method is the opposite of the other, where we allow
I-LC and Poss to go either way. There was a pairwise 58% concordance between
SIFT and PMUT, where we allowed SIFT I-LC to match to either PMUT
pathological or PMUT neutral; 87% concordance between SIFT and PolyPhen,
where we allowed SIFT I-LC to match to anything PolyPhen; and 67%
concordance between PMUT and PolyPhen where we allowed SIFT I-LC to
match to anything and PolyPhen Poss to match to anything.
doi:10.1371/journal.pone.0013584.t001
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13584Figure 2. Results from simulation study comparing power for rare variant analysis approaches. 500 simulations were based on
haplotype distribution for each of 13 deep sequenced candidate genes, and averaged. 500 permutations were run per test. Information for each
situation on the bottom of each plot consists of three parts that indicate the test used: ak (‘C’ for constant, ‘W’ for weighted by allele frequency); sk
(‘z={’ if signed, ‘z’ if constant); and the range of groupings vk (‘NS’ for nonsynonymous, ‘F’ for all protein coding, ‘*F’ for nongenerating protein
coding, ‘MAF’ for all MAF, ‘step’ for step-up, and ‘Perf’ for the exact generating alleles when appropriate). Results in plots A-C are sorted by the plot
that has the highest area, i.e., the most powerful overall. In D, each value of F indicates how much common variants affect disease and must be
considered separately; to emphasize this, we have sorted by the power when F~5.
doi:10.1371/journal.pone.0013584.g002
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13584Figure 3. Further results comparing power across rare variant approaches. Results in Figures A and B show the effect of having both
deleterious and protective rare variants. Figures C and D switches to a continuous trait, with Figure D showing the effect of having both deleterious
and protective rare variants. Results are sorted by the plot that has the highest area, i.e., the most powerful overall. See the Figure 2 legend for
additional details about the different simulations.
doi:10.1371/journal.pone.0013584.g003
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13584considered here. Of course, when one knows the underlying
disease model, aggregating rare variants to reflect this information
will excel. In practice, however, combining rare variants may
require strong and sometimes conflicting assumptions; softening
such assumptions with a hierarchical model may prove valuable
for rare variant analyses. Software for the approaches considered
here is freely available in the R package ‘‘thgenetics’’ available
from CRAN (http://cran.r-project.org/).
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